Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036341 (
schizophrenia
)
60,220
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Selenium binding protein 1
(
SELENBP1
) messenger RNA (mRNA) has previously been shown to be upregulated in the brain and blood from subjects with
schizophrenia
. We aimed to validate these findings in a new cohort using real-time PCR in Brodmann's Area (BA) 9, and to determine the disease specificity of increased
SELENBP1
expression by measuring
SELENBP1
mRNA in subjects with major depressive disorder and bipolar disorder. We then extended the study to include other cortical regions such as BA8 and BA44.
SELENBP1
mRNA was higher in BA9 (P = 0.001), BA8 (P = 0.003) and BA44 (P = 0.0007) from subjects with
schizophrenia
. Conversely, in affective disorders, there was no significant difference in
SELENBP1
mRNA in BA9 (P = 0.67), suggesting that the upregulation may be diagnosis specific. Measurement of SELENBP1 protein levels showed that changes in mRNA did not translate to changes in protein. In addition, chronic treatment of rats with antipsychotics did not significantly affect the expression of Selenbp1 in the cortex (P = 0.24). Our data show that elevated
SELENBP1
transcript expression is widespread throughout the prefrontal cortex in
schizophrenia
, and confirm that this change is a consistent feature of
schizophrenia
and not a simple drug effect.
...
PMID:SELENBP1 expression in the prefrontal cortex of subjects with schizophrenia. 2624 53